* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Demographic and Clinical Characteristics of Rheumatoid Arthritis
Survey
Document related concepts
Transcript
Demographic and Clinical Characteristics of Rheumatoid Arthritis patients in some Arab States: Preliminary analysis Mohammed Hammoudeh Division of Rheumatology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar Member of Middle East Rheumatoid Arthritis Consortium (MERAC) Saskia Mandey, Mohammed Hammoudeh, Ziyad Mahfoud, Wessam G. Elhaq, Marjonneke J Mook-Kanamori , Rawan Shayboub, Samar Al Emadi, Humeira Badsha, Imad Uthman, Hussein Halabi, Basel Masri, Layla Kazkaz, Robert M. Plenge, Cindy McKeon, Thurayya Arayssi 1 Disclaimer Introduction As faculty of Weill Cornell Medical College in Qatar we are committed to providing transparency for any and all external relationships prior to giving an academic presentation. Mohammed Hammoudeh M.D.FACP I DO NOT have a financial interest in commercial products or service. RA in the Middle East Introduction • There are few systemic large studies of RA in the ME • 15 studies, largest 160 patients, single center – – – – – – RA is more common in females High proportion of RF positivity Association with SE Conflicting results of severity Delay in initiation of therapy 1,2 Low use of DMARDS 1,2 Current study: Genetic studies of Rheumatoid Arthritis in some Arab States (GRAAS) 1. 2. Badsha H et al. Ann Rheum Dis 66, 835 (2007) Badsha H et al. Clin Rheumatol 27, 739-42 (2008) Genetic studies of Rheumatoid Arthritis in some Arab States Introduction Goal: • Investigate the genetic basis of RA in the Middle East by collecting at least 2000 RA and 2000 controls from 5 Rheumatology Centers across 5 Arab States. Genetic studies of Rheumatoid Arthritis in some Arab States Introduction Goal: – Genome Wide Association Study (GWAS) that will test for >30 identified risk alleles identified in European and North American populations Objective of this Presentation Introduction -So far 500 patients are recruited (350 RA and 150 Control ) Objective of this Presentation Introduction Describe the demographic and clinical characteristics of the first 150 Rheumatoid Arthritis patients from 5 countries in the Middle East recruited to date ( OCTOBER 2012FEBRUARY 2013). Inclusion Criteria Introduction • • • • Self reported Arab ancestry Age > 18 RA diagnosed per the ACR criteria Ability to provide informed consent Data Collection Introduction • Two sets of data were collected: – Demographic and clinical data – Ancestry data, based on self-reported ancestry • All data entry is web-based and centralized at WCMC-Q Introduction Results Nationality Introduction Nationality (%) 30 Nationality (regions) North 0% Africa 14% 25 0% percentage (%) 20 Gulf 49% Levant 37% 15 10 5 0 Gulf Levant North Africa Analysis done on 150 patients in February 2013 Demographics/ Clinical Introduction Demographic/ clinical characteristics Mean (SD) Age in years 49.9 (12.2) Age at diagnosis in years 38.9 (12.7) Disease Duration in years 11.1 (9.5) Demographics/Clinical characteristics Gender Female Male Number Percentage 135 15 90 10 38 12 25.3 8 4 2.7 68 82 45.3 54.7 77 73 51.3 48.7 93 62.1 Family member with RA Yes I don't know Extra-articular manifestation Yes Result of Anti CCP Positive Negative Result of Rheumatoid Factor Positive Negative Anti-CCP and/or RF positive Analysis done on 150 patients in February 2013 Clinical history Introduction Clinical history characteristics History of Autoimmune Disease Yes No History of vascular disease Yes No Diabetes Yes type 1 Yes type 2 No Number Percentage 10 140 6.7 93.3 9 141 6 94 2 16 132 1.3 10.7 88 Analysis done on 150 patients in February 2013 Demographics Introduction Demographic characteristics Number Percentage Married 120 80 Single 16 10.7 Divorced/ Separated/ Widowed 14 9.3 No formal education/ primary school 51 34 Middle/ Secondary School 49 32.7 University 50 33.3 Marital Status Education Analysis done on 150 patients in February 2013 Lifestyle Introduction Clinical characteristics Cigarette smoking Current Past never Number of years smoking cigarettes Mean (SD) [range] Shisha smoking Current Past never Number of years smoking shisha (in years) Mean (SD) [range] Number Percentage 24 8 118 16 5.3 78.7 17.6 (13.1) [1-45] 10.7 2 87.3 16 3 131 7.8 (10.1) [1-38] Analysis done on 150 patients in February 2013 Medications Introduction % (percentage) Medication Use (in percentage) 100 90 80 70 60 50 40 30 20 10 0 Yes Never 86% of the patients are using Methotrexate; Analysis done on 150 patients in February 2013 Current Users • • • • • • • • • • Introduction Methotrexate Oral steroids HCQ SSZ Leflunamide Etanrcep Infliximab Adalimumab Rituximab Total on Biologics 60% 35% 22% 5% 4.5% 11% 4% 10% 12% 37% Conclusions Introduction • The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases Conclusions Introduction • The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases • RF positivity and CCP positivity are low • . Conclusions Introduction • The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases • RF positivity and CCP positivity are low • 1/3 of patients are illiterate, which may impact compliance and disease outcome Conclusions Introduction • The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases • RF positivity and CCP positivity are low • 1/3 of patients are illiterate, which may impact compliance and disease outcome • Compared to the study done by Badsha et al, there is an increase in the use of Methotrexate (36% vs. 86%) Conclusions Introduction • The patient population of this study is relatively young in comparison to mean age (56.2 years) in the other large databases • RF positivity and CCP positivity are low • 1/3 of patients are illiterate, which may impact compliance and disease outcome • Compared to the study done by Badsha et al, there is an increase in the use of Methotrexate (36% vs. 86%) • 37% of our RA patients are on biologics ( in Europe 10-30% , in USA 40% ) Future Plans Introduction • Analyze the demographic and clinical data on a regular basis • Encourage more centers to join MERAC Acknowledgements Introduction Weill Cornell Medical College-Qatar Saskia Mandey Ziyad Mahfoud Wessam G. Elhaq Marjonneke Mook-Kanamori Cindy McKeon Rawan Shayboub Thurayya Arayssi Hamad Medical Corporation, Doha, Qatar Mohammed Hammoudeh Samar Al Emadi Al Biraa Arthritis and Bone Clinic, Dubai, UAE Humeirah Badsha American University of Beirut, Lebanon Imad Uthman King Faisal Specialist Hospital & Research center, Jeddah, Kingdom of Saudi Arabia Hussein Halabi Jordan Hospital, Amman, Jordan Basel Masri Tishreen Hospital, Damascus, Syria Layla Kazkaz Broad Institute, Cambridge, MA, USA Robert Plenge Introduction • THANK YOU